Home  > Technologieangebote

Modulation of ß-Catenin signalling for the treatment of cardiovascular diseases

Reference Number TO 03-00230


ß-catenin, one of the key regulator molecules of Wnt signalling pathway has been described within several clinical syndromes like cancer diseases. 


The present technology provides ß-catenin as a target in cardiovascular diseases. In vivo data derived from transgenic mouse models indicate a hypertrophy and enforcement of myocard action indicating a therapeutic use in cardiac repair upon nuclear depletion of ß-catenin. 

Commercial Opportunity

In-licensing of know-how and IP for target and validation, (pre-)clinical testing and development of therapeutics.

Patent Situation

PCT WO2008/122440
EP and US pending

Further Reading

  • Baurand et al., Circ Res. 2007; 100(9):1353-62.
  • Zelarayan et al, Cell Cycle. 2007, Jun 26;6(17) [Epub ahead of print]